骨粗鬆症治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Osteoporosis - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0561
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:318
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Osteoporosis – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis – Pipeline Review, H2 2019, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteoporosis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 8, 6, 21, 1, 57, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 12 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteoporosis – Overview
Osteoporosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Osteoporosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteoporosis – Companies Involved in Therapeutics Development
Abreos Biosciences Inc
Addpharma Inc
Aerami Therapeutics
Affilogic SAS
AgeX Therapeutics Inc
AlphaMab Co Ltd
Altum Pharmaceuticals Inc
Amgen Inc
Aryogen Pharmed Co
Axsome Therapeutics Inc
Bainan Biotech ApS
BIOCND Inc
Biosion Inc
Bone Biologics Corp
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cellatoz Therapeutics Inc
ChoDang Pharm Co Ltd
Chugai Pharmaceutical Co Ltd
Citragen Pharmaceuticals Inc
Corium International Inc
CSPC Pharmaceutical Group Ltd
Daewoong Pharmaceutical Co Ltd
Dong Wha Pharma Co Ltd
Eli Lilly and Co
EndoCeutics Inc
Enesi Pharma Ltd
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Evgen Pharma Plc
Genor BioPharma Co Ltd
GlycoNex Inc
GPN Therapeutics Inc
Haoma Medica Ltd
Helixmith Co Ltd
Histide AG
HNB Therapeutics LLC
Huons Co Ltd
Huons Global Co Ltd
IMGENEX India Pvt Ltd
Immunwork Inc
InnoPharmaScreen Inc
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd
Intas Pharmaceuticals Ltd
Ipsen SA
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Kolmar Pharma Co Ltd
Kyoto Pharmaceutical Industries Ltd
LBL Biotech Corp
Lead Discovery Center GmbH
Lupin Ltd
Luye Pharma Group Ltd
Max Biopharma Inc
Merck & Co Inc
Mesentech Inc
Metabolab Inc
Millendo Therapeutics Inc
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
NovMetaPharma Co Ltd
Omeros Corp
Ortho Regenics Pvt Ltd
Paras Biopharmaceuticals Finland Oy
Pfenex Inc
PhytoHealth Corp
Qilu Pharmaceutical Co Ltd
R Pharm
Regenerative Arthritis & Bone Medicine Inc
Reliance Life Sciences Pvt Ltd
Ribomic Inc
Sandoz International GmbH
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Biomabs Pharmaceuticals Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong Pharm Co Ltd
Stelis Biopharma Pvt Ltd
Suzhou Stainwei Biotech Inc
Taithera Inc
Terpenoid Therapeutics Inc
The National Institute for Biotechnology in the Negev Ltd
Tritech Biopharmaceuticals Co Ltd
TSH Biopharm Corporation Ltd
Uni-Bio Science Group Ltd
USV Pvt Ltd
Vibe Pharmaceuticals LLC
Vidasym Inc
Viking Therapeutics Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Yooyoung Pharm Co Ltd
Osteoporosis – Drug Profiles
Osteoporosis – Dormant Projects
Osteoporosis – Discontinued Products
Osteoporosis – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Osteoporosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Osteoporosis - Pipeline by Abreos Biosciences Inc, H2 2019
Osteoporosis - Pipeline by Addpharma Inc, H2 2019
Osteoporosis - Pipeline by Aerami Therapeutics, H2 2019
Osteoporosis - Pipeline by Affilogic SAS, H2 2019
Osteoporosis - Pipeline by AgeX Therapeutics Inc, H2 2019
Osteoporosis - Pipeline by AlphaMab Co Ltd, H2 2019
Osteoporosis - Pipeline by Altum Pharmaceuticals Inc, H2 2019
Osteoporosis - Pipeline by Amgen Inc, H2 2019
Osteoporosis - Pipeline by Aryogen Pharmed Co, H2 2019
Osteoporosis - Pipeline by Axsome Therapeutics Inc, H2 2019
Osteoporosis - Pipeline by Bainan Biotech ApS, H2 2019
Osteoporosis - Pipeline by BIOCND Inc, H2 2019
Osteoporosis - Pipeline by Biosion Inc, H2 2019
Osteoporosis - Pipeline by Bone Biologics Corp, H2 2019
Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Osteoporosis - Dormant Projects, H2 2019
Osteoporosis - Discontinued Products, H2 2019
Osteoporosis - Discontinued Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

Abreos Biosciences Inc
Addpharma Inc
Aerami Therapeutics
Affilogic SAS
AgeX Therapeutics Inc
AlphaMab Co Ltd
Altum Pharmaceuticals Inc
Amgen Inc
Aryogen Pharmed Co
Axsome Therapeutics Inc
Bainan Biotech ApS
BIOCND Inc
Biosion Inc
Bone Biologics Corp
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cellatoz Therapeutics Inc
ChoDang Pharm Co Ltd
Chugai Pharmaceutical Co Ltd
Citragen Pharmaceuticals Inc
Corium International Inc
CSPC Pharmaceutical Group Ltd
Daewoong Pharmaceutical Co Ltd
Dong Wha Pharma Co Ltd
Eli Lilly and Co
EndoCeutics Inc
Enesi Pharma Ltd
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Evgen Pharma Plc
Genor BioPharma Co Ltd
GlycoNex Inc
GPN Therapeutics Inc
Haoma Medica Ltd
Helixmith Co Ltd
Histide AG
HNB Therapeutics LLC
Huons Co Ltd
Huons Global Co Ltd
IMGENEX India Pvt Ltd
Immunwork Inc
InnoPharmaScreen Inc
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd
Intas Pharmaceuticals Ltd
Ipsen SA
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Kolmar Pharma Co Ltd
Kyoto Pharmaceutical Industries Ltd
LBL Biotech Corp
Lead Discovery Center GmbH
Lupin Ltd
Luye Pharma Group Ltd
Max Biopharma Inc
Merck & Co Inc
Mesentech Inc
Metabolab Inc
Millendo Therapeutics Inc
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
NovMetaPharma Co Ltd
Omeros Corp
Ortho Regenics Pvt Ltd
Paras Biopharmaceuticals Finland Oy
Pfenex Inc
PhytoHealth Corp
Qilu Pharmaceutical Co Ltd
R Pharm
Regenerative Arthritis & Bone Medicine Inc
Reliance Life Sciences Pvt Ltd
Ribomic Inc
Sandoz International GmbH
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Biomabs Pharmaceuticals Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong Pharm Co Ltd
Stelis Biopharma Pvt Ltd
Suzhou Stainwei Biotech Inc
Taithera Inc
Terpenoid Therapeutics Inc
The National Institute for Biotechnology in the Negev Ltd
Tritech Biopharmaceuticals Co Ltd
TSH Biopharm Corporation Ltd
Uni-Bio Science Group Ltd
USV Pvt Ltd
Vibe Pharmaceuticals LLC
Vidasym Inc
Viking Therapeutics Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Yooyoung Pharm Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨粗鬆症治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆